



Ameliorative effects of pirfenidone in chronic kidney disease

Samad Ghodrati^{1,2}, Yeganeh Ragati Haghi³, Jyoti Baharani⁴, Akshaya Joseph⁵, Niloufar Alimohammadi⁶, Farzad Koosha⁷, Leila Mostafavi⁸, Aiyoub Pezeshgi^{1,2*}

¹Zanjan Metabolic Disease Research Center, Zanjan University of Medical Sciences, Zanjan, Iran

²Department of Internal Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

³Massachusetts College of Pharmacy and Health Sciences - Worcester Campus: Worcester, MA, USA

⁴University Hospitals Birmingham, B95SS, UK

⁵Department of Pharmaceutical Sciences at the University of British Columbia, Vancouver, British Columbia, Canada

⁶Department of Medicine, New York University, School of Medicine, New York, New York, USA

⁷Department of Oral Biology and Pathology, State University of New York at Stony Brook, NY, USA

⁸Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

ARTICLE INFO

Article Type:

Review

Article History:

Received: 23 October 2021

Accepted: 3 December 2021

Published online: 10 January 2022

Keywords:

Pirfenidone

Chronic kidney disease

Transforming growth factor beta

End-stage renal disease

ABSTRACT

Renal fibrosis is the hallmark of advanced chronic kidney disease (CKD), which is characterized by excessive accumulation of extracellular matrix (ECM) proteins and plays a central role in the pathogenesis and progression of CKD to end-stage renal disease (ESRD). The molecular and cellular substances of kidney fibrosis include growth factors, such as fibroblast growth factor (FGF), transforming growth factor beta (TGF- β) and platelet-derived growth factor (PDGF), alongside cytokines (like interleukin-1b) and metalloproteinases. Therefore, these factors can be evaluated as possible targets for anti-fibrotic agents. Among the mediators of fibrosis, TGF- β is the dominant facilitator of renal fibrosis that induces ECM construction and accumulation. Numerous studies have focused on the inhibition of TGF- β and its downstream targets for the treatment of renal disease. Abolition of TGF- β mRNA expression was found to be the mechanism of anti-fibrotic drug, pirfenidone, in the heart and kidneys of diabetic rats. Various investigations have shown the impact of pirfenidone in diminishing kidney fibrosis, with studies containing patients diagnosed with subtotal nephrectomy, diabetic kidney disease and unilateral ureteral obstruction (UUO), administered drugs such as cyclosporine, tacrolimus, doxorubicin and vanadate. Several therapeutic drugs for fibrosis reduce only one of the oxidative, inflammatory or profibrogenic markers, while pirfenidone targets all three of these markers and therefore, seems to be a particularly valuable drug.

Implication for health policy/practice/research/medical education:

Various studies have shown the impact of pirfenidone in diminishing kidney fibrosis in chronic kidney disease.

Please cite this paper as: Ghodrati S, Ragati Haghi Y, Baharani J, Joseph A, Alimohammadi N, Koosha F, Mostafavi L, Pezeshgi A. Ameliorative effects of pirfenidone in chronic kidney disease. J Nephropharmacol. 2022;11(x):x-x. DOI: 10.34172/npj.2021.xx

Introduction

Pirfenidone is a synthetic drug characterized by a small-molecular weight and simple chemical structure (5-methyl-1-phenyl-2(1H)-pyridone). It was primarily accepted as an anthelmintic and antipyretic drug; however, it also has anti-fibrotic and anti-inflammatory activities in a variety of *in vitro*, animal and cell-based models (lung, liver and kidney) (1). Pirfenidone was approved for treatment of idiopathic pulmonary fibrosis (IPF) in 2011 and was launched commercially by InterMune under the trade name Esbriet (2).

After oral administration, it is quickly absorbed by the

gastrointestinal (GI) tract since it is highly hydrophilic and can move through cell membranes with relative ease and without requiring a receptor. After one to two hours, it reaches its maximum level in blood and is almost entirely excreted in urine within six hours. It has the advantage of possessing very low toxicity with minor side effects such as nausea, dizziness, headache, photosensitivity and gastrointestinal effects (3).

The anti-fibrotic effects of pirfenidone have also been demonstrated in other models of tissue fibrosis such as bleomycin-induced pulmonary fibrosis (4), multiple sclerosis (5) and liver fibrosis associated with chronic

hepatitis C infection (6).

Renal fibrosis

Chronic kidney disease (CKD) heavily contributes to mortality and morbidity worldwide. Renal fibrosis is the hallmark of CKD progression, characterized by excessive accumulation of extracellular matrix (ECM) proteins, which plays a central role in the pathogenesis and progression of CKD to end-stage renal disease (ESRD) (1). CKD is often a comorbid condition in patients with IPF as up to 30% of IPF patients are also afflicted with underlying chronic renal failure (stages 3-5). Individuals with both conditions demonstrate worse prognosis, decreased survival, greater incidence of hypertension and ischemic heart disease, alongside lower lung diffusion capacity and exercise capacity than those who suffer from IPF without CKD (7).

Progression of fibrosis involves both cell-intrinsic/autonomous and ECM-driven mechanisms. Activated myofibroblasts are the main ECM component causing fibrosis. The cellular and molecular mediators of kidney fibrosis include growth factors, such as fibroblast growth factor (FGF), transforming growth factor beta (TGF- β) and platelet-derived growth factor (PDGF), alongside cytokines (such as interleukin-1b), imbalances in metalloproteinases and their inhibitors, which may all act as suitable targets of antifibrotic drugs (8).

TGF- β -induced ECM production and accumulation is the central mediator of renal fibrosis, with numerous studies focusing on the inhibition of TGF- β and its downstream targets for the treatment of renal disease. Diabetic nephropathy is associated with increased TGF- β messenger RNA (mRNA) expression and induced progressive renal disease, which is characterized by thickening of the glomerular basement membrane, mesangial expansion, accumulation of matrix proteins and proteinuria. The abolition of TGF- β mRNA expression is allegedly the mechanism for the antifibrotic medications and the anti-fibrotic effect of pirfenidone in the hearts and kidneys of diabetic rats. Blocking TGF- β may have important hemodynamic effects relevant to diabetic complications. Additionally, a long-term and continuous total blockade of glomerular TGF- β may decrease proteinuria (9). However, inhibition of TGF- β reduces renal disease (10-14).

Mechanism of action of pirfenidone

In a study, mitogen activated protein kinase (MAPK) is activated in the obstructed kidney of rats with unilateral ureteral obstruction (UUO) and in TGF- β -treated renal tubular epithelial cells. Pirfenidone is able to inhibit tubular epithelial-mesenchymal transition (EMT) and renal fibrosis. Pirfenidone is also capable to reduce cellular proliferation *in vivo* and *in vitro* through downregulating the MAPK pathway (13-18). Chen et al showed that

pirfenidone inhibits caspase-9 and caspase-3 cleavage in renal proximal tubular cells and inhibited apoptosis of epithelial tubular cells in a dosage-dependent fashion. Therefore, pirfenidone may also reduce oxidative stress by inhibiting the mitochondrial apoptotic-signaling pathway in renal tubular cells (19).

Pirfenidone at the concentration with having anti-fibrotic impacts is very toxic *in-vitro*. This effect could explain the inconsistencies between various studies on experimental models (20-25).

The renoprotective properties and mechanism of pirfenidone in a rat model with hypertension-induced renal injury was also investigated and pirfenidone was shown to prevent renal injury by its anti-fibrotic and anti-oxidative stress effects via the downregulation of TGF- β -Smad2/3 signaling, improvement of MMP9/TIMP1 balance and suppression of fibroblast proliferation, without effect on the expression of tumor necrosis factor alpha protein, macrophage, T cell infiltration or plasma interleukin 1-beta levels (26).

Various therapeutic drugs for fibrosis reduction affect only one of the oxidative, inflammatory or a profibrogenic markers whereas pirfenidone targets all three markers, introducing it as a promising treatment. Hence, pirfenidone might be favorable not only in experimental studies, but also in human fibrotic disorders (3).

Pirfenidone in renal fibrosis

The TGF- β function is influenced by non-Smad and Smad signaling pathways in most cases. TGF- β /Smad signaling pathways often comprise effective therapeutic targets for treatment of renal fibrosis and inflammation. The targets, Smad2 and Smad3, are regulated by specific microRNAs, phosphorylation and nuclear translocation. Therefore, inhibition of Smad3 and up-regulation of Smad7, which improves the TGF- β /Smad signaling, may provide an effective strategy to prevent renal fibrosis and CKD progression (Figure 1) (10).

A study on animal models by Chen et al confirmed that treatment with an anti-TGF- β antibody in diabetic nephropathy models improved glomerular matrix expansion and renal function however it did not affect proteinuria and macromolecular permeability (11). Unfortunately, most of the completed clinical trials about anti-TGF- β therapy have small sample sizes and were provided by definitive results. The plasminogen activator inhibitor-1 (PAI-1) and PDGF were associated with TGF- β and renal fibrosis in the epithelial cells of proximal tubules in a rat model. Pirfenidone inhibits these fibrosis cascades, which results in similar antifibrotic effects in the kidney (12,25-28). Fibroblasts have been universally recognized in tubulointerstitial injury, where their presence is a marker of disease progression. Recently, pirfenidone administrated in rats with UUO was shown to ameliorate progressive fibrosis and reduce established




Figure 1. Various roles of Smads in renal fibrosis. P represents phosphorylated Smad. The phosphorylated Smad2 and Smad3 bind to Smad4 and form the Smad complex, which translocates into the nucleus and regulates the target gene transcription, including Smad7. Blue lines indicate pathogenic regulation pathways, while red arrows represent protective regulation pathways. Smad2 and Smad3 act as TGF- β /activin signaling and Smad 4 acts as transport of Smad2 and Smad3. Smad7 is an inhibitory Smad that functions to block Smad2/3 activation.

scarring, possibly acting as a novel anti-fibrotic agent. It has been shown that pirfenidone decreased spinal muscular atrophy and connective tissue growth factor protein expression. Effects of pirfenidone were independent of cell toxicity. Down-regulation of renal fibroblast activation and proliferation are mechanisms of action specific to pirfenidone (13).

Pirfenidone reduced glomerulosclerosis effectively in diabetic mice and in an animal model with subtotal nephrectomy by decreasing tubulointerstitial fibrosis. Moreover, it was shown in glomerular mesangial cells of mice that pirfenidone decreased TGF- β promoter activity, abolished TGF- β protein secretion, prevented Smad2-phosphorylation, and reduced reactive oxygen species (ROS) production induced by TGF- β (1-5).

In a study by Matsumoto et al, pirfenidone dramatically suppressed the progression to renal dysfunction in CKD patients with glomerular filtration rate (GFR) <60 mL/min/1.73 m² for six months or longer after starting treatment (14).

A study on hemodialysis patients with a history of sclerosing peritonitis demonstrated pirfenidone to be well tolerated even in ESRD patients without the need for dose reduction (15). An open-label, single-center, phase III pilot trial on 18 patients diagnosed with focal segmental glomerulosclerosis demonstrated treatment with pirfenidone slowed renal function decline rate by almost 25% (16). In a randomized, placebo-controlled phase II trial involving 77 individuals with diabetic nephropathy and albuminuria, the estimated GFR (eGFR) improved by 3.3 mL/min/1.73 m² in the group treated with 1200 mg of pirfenidone compared to 2.2 mL/min/1.73 m² in the

placebo treated group at 54 weeks of treatment. However, no changes were observed in proteinuria or urinary TGF- β excretion (29). It should be noted that eGFR increased only in the lowest pirfenidone dosage group (1200 mg) and decreased in the higher dosage group (2400 mg), similar to the placebo group (17). Based on this study, it appears that pirfenidone may primarily exert its beneficial effects by reducing fibrosis in the tubulointerstitium instead of causing glomerular changes or affecting albuminuria and proteinuria.

Similarly, an open-label, nonrandomized pilot trial evaluated the safety of a new formulation of prolonged-release pirfenidone (2400 mg daily) in 18 patients with CKD, specifically with focal and segmental glomerular hyalinization (FSGH) over 60 months. This study found that the prolonged release pirfenidone slowed renal function decline significantly in CKD patients. While, eGFR, creatinine, cystatin C, urea, hemoglobin and hepatic transaminases levels was not changed in this study, however proteinuria was improved. This new pharmaceutical formulation of pirfenidone displayed minor side effects and increased tolerance compared to pirfenidone preparations used in previous studies. Prolonged release pirfenidone can safely be administered as an adjuvant therapy in patients with CKD (18).

The beneficial impact of pirfenidone in diminishing kidney fibrosis has been detected in various investigations, consisting of models of subtotal nephrectomy (19-22), diabetic nephropathy (14), cyclosporine (23), tacrolimus (24), doxorubicin (25) and vanadate (26) as explained in detail below.

A study by Takakura et al (20) detected that prophylactic therapy with pirfenidone diminished fibrosis by 80% with improvement of proteinuria as well as serum blood urea nitrogen and creatinine levels.

Shimizu et al (21) showed pirfenidone treatment inhibited 60% of collagen deposition after nephrectomy, associated with decreased presentation of collagen mRNAs and TGF- β in the subtotal 5/6 nephrectomy model, and was also associated with improved creatinine clearance.

UUO is a well-characterized model of experimental renal disease, which leads to tubulointerstitial fibrosis. The mRNA for collagen types IV and I, TGF- β and matrix metalloproteinase-2 (MMP-2) are upregulated in this model, while hydroxyproline content is increased in the post-obstructed kidney. After three days UUO onset, pirfenidone concentrations increased in cortical fibroblasts isolated from kidneys, causing a reduction in cell proliferation, smooth muscle actin, connective tissue growth factor presentation and hydroxyproline, without effects on collagen. Therefore, pirfenidone was shown to prevent renal damage, renal fibrosis, and irreversible renal failure in UUO models (22).

In isolated perfused kidneys of rats, streptozotocin treatment induced diabetes and temporarily decreased

renal function and urine flow rates. Treatment with pirfenidone and spironolactone caused reversal of kidney and cardiac fibrosis and also weakened enhanced diastolic stiffness, which emphasizes the dynamic nature of the ECM. This study also showed high diabetes-induced cardiac stiffness to be lowered by pirfenidone (23).

Recent studies showed that combination treatment of pirfenidone with candesartan in rats with chronic anti-glomerular basement membrane glomerulonephritis demonstrated an additive effect compared to pirfenidone alone. Combination treatment improved absorption of droplets, reduction in proteinuria and decrease of cortical collagen I mRNA expression (28).

Pirfenidone also decreased sclerosis scores and proteinuria levels at three months using FGS/Kist mice as a model of spontaneous progressive glomerulosclerosis. However, this study showed no significant differences regarding effective therapy after the treatment period between the pirfenidone and control groups. It is suggested that longstanding administration of pirfenidone is required to reduce the development of kidney glomerulosclerosis and to ameliorate kidney activity in the FGS/Kist mice (29).

The antifibrotic effects of pirfenidone in a vanadate-induced renal fibrosis model in rats were also explored. Therapy with pirfenidone diminished vanadate-induced elevation of renal weight, collagen substance, RNA content and hydroxyproline concentrations. Morphological assessment disclosed that the intensity of the injury decreased to a mild degree after treatment with pirfenidone for 41 days, while it was of moderate to severe degree in the vanadate-treated group (26).

Chronic cyclosporine nephrotoxicity is characterized by tubulointerstitial fibrosis with increased TGF- β . Treatment with pirfenidone improved cyclosporine-induced fibrosis approximately 50%, decreased TGF- β expression about 80% and reduced the quantity of apoptosis-positive cells. Pirfenidone down-regulated mRNA expression of cyclosporine-induced p53, Fas-ligand and caspase 3 presentation especially in kidney epithelial cells (30). Reduction in apoptosis through apoptosis-regulatory genes acts as a mechanism underlying antifibrotic properties of pirfenidone (30).

Nephrotoxicity induced by tacrolimus modifies expression of mRNA for genes implicated in matrix metabolism and therefore father kidney transplantation dysfunction and subsequent renal failure. It is suggested that pirfenidone may decrease the fibrotic potential of tacrolimus, decreasing tissue inhibitors of metalloproteinases-1 (TIMP-1) mRNA and collagen III expression, which plays a crucial role in ECM composition (30).

More recent studies have shown pirfenidone to prevent acute renal damage induced by bilateral ischemia in

rats. Pirfenidone is suggested to be a promising drug to reduce renal injury induced by ischemia and improve reperfusion by recovering nitric oxide production (31). The advantages of pirfenidone surpass its adverse events including dyspepsia, abdominal discomfort, sedation and fatigue.

Conclusion

Numerous investigations demonstrated the beneficial impact of pirfenidone in decreasing kidney fibrosis under various models such as UUO, diabetic kidney disease, subtotal nephrectomy, cyclosporine, tacrolimus and doxorubicin therapy as explored above. Several therapeutic drugs for fibrosis reduce only one of oxidative, inflammatory, or profibrogenic markers whereas pirfenidone targets all three markers and therefore, seems to be a particularly valuable drug. Various studies uncovered pirfenidone as a medication that can slow kidney insufficiency, and even recover kidney structure and function in individuals with diabetic kidney disease.

Authors' contribution

Primary draft by SG and AP. First edit by JB, YRH. Second edit by NA, FK and LM. All authors read and signed the final manuscript.

Conflicts of interest

The authors declare that they have no competing interests.

Ethical issues

Ethical issues (including plagiarism, data fabrication and double publication) were completely observed by the authors.

Funding/Support

None

References

- Schaefer CJ, Ruhmundt DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. *Eur Respir Rev*. 2011;20:85-97. doi: 10.1183/09059180.00001111.2.
- King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med*. 2014;370:2083-92. doi: 10.1056/NEJMoa1402582.
- Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. *Fibrogenesis Tissue Repair*. 2010;3:16. doi: 10.1186/1755-1536-3-16.
- Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. *J Lab Clin Med*. 1995; 125:779-85.
- Walker JE, Giri SN, Margolin SB. A double blind, randomized, controlled study of oral pirfenidone for

- treatment of secondary progressive multiple sclerosis. *Mult Scler*. 2005;11:149-58. doi: 10.1191/1352458505ms1134oa.
6. Armendáriz-Borunda J, Islas-Carbajal MC, Meza-García E, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. *Gut*. 2006;55:1663-5. doi: 10.1136/gut.2006.107136.
 7. Ikezoe K, Handa T, Tanizawa K, Yokoi H, Kubo T, et al. Aihara K. et al. Chronic kidney disease predicts survival in patients with idiopathic pulmonary fibrosis. *Respiration* 2017;94:346-354. doi: 10.1159/000478787
 8. Eddy AA. Molecular insights into renal interstitial fibrosis. *J Am Soc Nephrol* 1996;7:2495-2508.
 9. Isaka Y. Targeting TGF- β signaling in kidney fibrosis. *Int J Mol Sci*. 2018; 19: 2532. doi: 10.3390/ijms19092532.
 10. Chen L, Yanga T, Lu D-W, Zhao H, Feng Y-L, Chen H, et al. Central role of dysregulation of TGF- β /Smad in CKD progression and potential targets of its treatment. *Biomed. Pharmacother*. 2018;101:670-81. doi: 10.1016/j.biopha.2018.02.090.
 11. Chen S, Cruz I-de, Jim B, Hong SW, Isono M, Ziyadeh FN. Reversibility of established diabetic glomerulopathy by anti-TGF- β antibodies in db/db mice. *Biochem Biophys. Res Commun*. 2003;300:16-22. doi: 10.1016/S0006-291X(02)02708-0.
 12. Takakura K, Tahara A, Sanagi M, Itoh H, Tomura Y. Antifibrotic effects of pirfenidone in rat proximal tubular epithelial cells. *Renal Failure*. 2012;34:1309-16. doi: 10.3109/0886022X.2012.718955.
 13. Hewitson TD, Kelnack KJ, Tait MG, Martic M, Jones CL, Margolin SB, et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. *J Nephrol*. 2001; 14:453-60.
 14. Matsumoto J, Sunohara K, Mori Y, Nagaya H, Inaba S. Effects of pirfenidone on renal function in patients with interstitial pneumonia. *Ren Fail*. 2021;43:879-881. doi: 10.1080/0886022X.2021.1925297.
 15. Taniyama M, Ohbayashi S, Narita M, Nakazawa R, Hasegawa S, Azuma N, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. *Eur J Clin Pharmacol* 1997;52:77-8. doi: 10.1007/s002280050252
 16. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. *Clin J Am Soc Nephrol*. 2007;2:906-13. doi: 10.2215/CJN.01050207.
 17. Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, et al. Pirfenidone for diabetic nephropathy. *J Am Soc Nephrol*. 2011;22:1144-51. doi: 10.1681/ASN.2010101049.
 18. Ojeda-Duran SA, Lyra-Gonzalez I, Meza-Rios A, Lucano-Landeros S, Sandoval-Rodriguez A, Mercado MVD, et al. Evaluation of safety of a newly formulated pirfenidone in chronic kidney disease: a non-randomized pilot study in Mexican patients. *J Ren Hepat Disord*. 2020;4:22-30. doi: 10.15586/jrenhep.2020.61.
 19. Chen J-F, Liu H, Ni H-F, Lv L-L, Zhang M-H, Zhang A-H, et al. Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats. *PLoS One*. 2013;8:e83593. doi: 10.1371/journal.pone.0083593.
 20. Ma X. Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: Through anti-fibrotic and anti-oxidative stress pathways. *Biomedical Research*. 2013;34:309-19.
 21. Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. *Kidney Int Suppl*. 1997;63:S239-43.
 22. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. *Kidney Int*. 1998;54: 99-109. doi: 10.1046/j.1523-1755.1998.00962.x.
 23. Brook NR, Waller JR, Bicknell GR, Nicholson ML. The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model. *Transplant Proc*. 2005;37:130-3. doi: 10.1016/j.transproceed.2004.12.150.
 24. Brook NR, Waller JR, Bicknell GR, Nicholson ML. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. *J Surg Res*. 2005;125:137-43. doi: 10.1016/j.jss.2004.12.007.
 25. Giri SN, Al-Bayati MA, Du X, Schelegle E, Mohr FC, Margolin SB. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. *Cancer Chemother Pharmacol* 2004;53:141-50. doi: 10.1007/s00280-003-0703-z.
 26. Al-Bayati MA, Xie Y, Mohr FC, Margolin SB. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. *Biochem Pharmacol*. 2002;64:517-25. doi: 10.1016/S0006-2952(02)01213-3.
 27. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. *Br J Pharmacol*. 2001;133:687-94. doi: 10.1038/sj.bjp.0704131.
 28. Leh S, Vaagnes Ø, Margolin SB, Iversen BM, Forslund T. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. *Nephrol Dial Transplant*. 2005;20:71-82. doi: 10.1093/ndt/gfh562
 29. Park HS, Bao L, Kim YJ, Cho IH, Lee CH, Hyun BH, et al. Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse. *J Korean Med Sci*. 2003;18:527-33. doi: 10.3346/jkms.2003.18.4.527.
 30. Li Z, Liu X, Wang B, Nie Y, Wen J, Wang Q, et al. Pirfenidone suppresses MAPK signaling pathway to reverse epithelial-mesenchymal transition and renal fibrosis. *Nephrology (Carlton)*. 2017;22:589-97. doi: 10.1111/nep.12831.
 31. Lima-Posada I, Fontana F, Pérez-Villalva R, Berman-Parks N, Bobadilla NA. Pirfenidone prevents acute kidney injury in the rat. *BMC Nephrol*. 2019;20:158. doi: 10.1186/s12882-019-1364-4.